Therapeutic implications of the effects of oral hypoglycaemic therapy on the enteroinsular axis in type 2 diabetes.

INTERVENTION: Product Name: GLP‐1 Pharmaceutical Form: Injection* Pharmaceutical form of the placebo: Injection* Route of administration of the placebo: Cutaneous use CONDITION: Type 2 diabetes PRIMARY OUTCOME: Main Objective: Effects of exogenous GLP‐1 with or without metformin or nateglinide on plasma DPPIV, GLP‐1 and the metabolic response to feeding in subjects with type 2 diabetes. Primary end point(s): Plasma glucose, insulin, C‐peptide, glucagon, DPPIV, GLP‐1 Secondary Objective: INCLUSION CRITERIA: Type 2 diabetes ‐ controlled with diet or single oral hypoglycaemic agent. ‐ HbA1C<7.5% Serum creat<150 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18‐64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range